Robeco Institutional Asset Management B.V. purchased a new position in shares of Healthequity Inc (NASDAQ:HQY) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 21,995 shares of the company’s stock, valued at approximately $1,026,000.
A number of other large investors have also recently added to or reduced their stakes in the business. Janus Henderson Group PLC grew its holdings in Healthequity by 627.9% in the 2nd quarter. Janus Henderson Group PLC now owns 2,113,030 shares of the company’s stock valued at $105,292,000 after buying an additional 1,822,732 shares in the last quarter. Eagle Asset Management Inc. acquired a new position in Healthequity in the 3rd quarter valued at $36,875,000. Wells Fargo & Company MN grew its holdings in Healthequity by 49.5% in the 3rd quarter. Wells Fargo & Company MN now owns 1,108,410 shares of the company’s stock valued at $56,063,000 after buying an additional 366,925 shares in the last quarter. Amussen Hunsaker & Associates LLC acquired a new position in Healthequity in the 2nd quarter valued at $11,598,000. Finally, Stifel Financial Corp grew its holdings in Healthequity by 456.5% in the 3rd quarter. Stifel Financial Corp now owns 216,335 shares of the company’s stock valued at $10,979,000 after buying an additional 177,462 shares in the last quarter. 98.63% of the stock is owned by hedge funds and other institutional investors.
In other Healthequity news, EVP Delano Ladd sold 26,405 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $43.32, for a total transaction of $1,143,864.60. Following the completion of the transaction, the executive vice president now owns 16,692 shares of the company’s stock, valued at approximately $723,097.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Frank Medici sold 13,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $52.14, for a total value of $677,820.00. Following the transaction, the director now directly owns 6,381 shares of the company’s stock, valued at approximately $332,705.34. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 820,726 shares of company stock valued at $42,080,968. 19.00% of the stock is owned by company insiders.
Healthequity Inc (HQY) traded up $0.71 during mid-day trading on Wednesday, reaching $53.36. The company’s stock had a trading volume of 786,600 shares, compared to its average volume of 504,180. Healthequity Inc has a twelve month low of $37.62 and a twelve month high of $55.31. The stock has a market capitalization of $3,290.00, a PE ratio of 73.27, a P/E/G ratio of 2.01 and a beta of 1.70.
Healthequity (NASDAQ:HQY) last issued its earnings results on Tuesday, December 5th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.13 by $0.04. Healthequity had a return on equity of 14.47% and a net margin of 21.08%. The firm had revenue of $56.80 million for the quarter, compared to analyst estimates of $55.27 million. During the same period in the previous year, the company posted $0.10 earnings per share. The business’s revenue was up 31.0% on a year-over-year basis. equities analysts predict that Healthequity Inc will post 0.73 earnings per share for the current year.
Several research firms recently weighed in on HQY. BidaskClub upgraded Healthequity from a “sell” rating to a “hold” rating in a research report on Tuesday, November 7th. Zacks Investment Research upgraded Healthequity from a “hold” rating to a “buy” rating and set a $57.00 price objective for the company in a research report on Saturday. JPMorgan Chase & Co. lowered their price objective on Healthequity from $52.00 to $51.00 and set an “overweight” rating for the company in a research report on Wednesday, January 24th. Cantor Fitzgerald raised their price objective on Healthequity from $56.00 to $60.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Finally, Robert W. Baird lifted their target price on Healthequity from $48.00 to $49.00 and gave the stock a “neutral” rating in a report on Wednesday, February 7th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $56.67.
WARNING: “Robeco Institutional Asset Management B.V. Buys Shares of 21,995 Healthequity Inc (HQY)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/14/robeco-institutional-asset-management-b-v-takes-position-in-healthequity-inc-hqy.html.
Healthequity Company Profile
HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.